Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Sotigalimab plus chemotherapie, met of zonder nivolumab, bij gemetastaseerd pancreascarcinoom
jan 2021 | Maag-darm-leveroncologie